A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models

Nature Communications

Volumn 6, Issue , 2015, Pages

  Bhattacharyya, Jayanta ^a   Bellucci, Joseph J ^a   Weitzhandler, Isaac ^a   McDaniel, Jonathan R ^a,b   Spasojevic, Ivan ^c,d   Li, Xinghai ^a   Lin, Chao Chieh ^c,e   Chi, Jen Tsan Ashley ^c,e   Chilkoti, Ashutosh ^a  

^a Duke University   (United States)

^b The University of Texas at Austin   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; NANOPARTICLE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPEPTIDE NANOPARTICLE; SMAD2 PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NANOCONJUGATE; PEPTIDE; RECOMBINANT PROTEIN;

AQUEOUS SOLUTION; BIOENGINEERING; CANCER; DRUG; HYDROPHOBICITY; NUMERICAL MODEL; PARTICLE SIZE; PEPTIDE; RECOMBINATION; TUMOR; WOMENS HEALTH;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DOWN REGULATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC50; IN VITRO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MICROTUBULE; MOLECULAR STABILITY; MOLECULAR WEIGHT; MOUSE; NEUROTOXICITY; NONHUMAN; PH; PROSTATE CANCER; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CELL SURVIVAL; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; PROSTATE TUMOR; TUMOR CELL LINE; ULTRASTRUCTURE;

MURINAE; MUS;

ALBUMIN-BOUND PACLITAXEL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MALE; MICE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOCONJUGATES; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PACLITAXEL; PEPTIDES; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938634258     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8939     Document Type: Article

References (52)

1. Scott, R. B. Cancer chemotherapy - the first twenty-five years. Br. Med. J. 4, 259-265 (1970).
2. Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
3. Lee, C. C., MacKay, J. A., Frechet, J. M. J. & Szoka, F. C. Designing dendrimers for biological applications. Nat. Biotechnol. 23, 1517-1526 (2005).
4. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
5. McDaniel, J. R. et al. Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation. Angew. Chem. Int. Ed. 52, 1683-1687 (2013).
6. MacKay, J. A. et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater. 8, 993-999 (2009).
7. Slichenmyer, W. J. & Von Hoff, D. D. New natural products in cancer chemotherapy. J. Clin. Pharmacol. 30, 770-788 (1990).
8. Bombuwala, K. et al. Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel. Beilstein J. Org. Chem. 2, 13 (2006).
9. Tejada-Berges, T., Granai, C. O., Gordinier, M. & Gajewski, W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev. Anticancer Ther. 2, 143-150 (2002).
10. Gradishar, W. J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 7, 1041-1053 (2006).
11. Tatham, A. S. & Shewry, P. R. Elastomeric proteins: biological roles, structures and mechanisms. Trends Biochem. Sci. 25, 567-571 (2000).
12. Meyer, D. E. & Chilkoti, A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat. Biotechnol. 17, 1112-1115 (1999).
13. Massey, J., Power, K. N., Manners, I. & Winnik, M. A. Self-assembly of a novel organometallic-inorganic block copolymer in solution and the solid state: nonintrusive observation of novel wormlike poly(ferrocenyldimethylsilane)-bpoly( dimethylsiloxane) micelles. J. Am. Chem. Soc. 120, 9533-9540 (1998).
14. Desai, N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 14, 282-295 (2012).
15. Cardone, R. A., Casavola, V. & Reshkin, S. The role of disturbed pH dynamics and the a+/H+ exchanger in metastasis. Nat. Rev. Cancer 5, 786-795 (2005).
16. Sorkin, A. & von Zastrow, M. Signal transduction and endocytosis: close encounters of many kinds. Nat. Rev. Mol. Cell Biol. 3, 600-614 (2002).
17. Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R. & Lluch, A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat. Rev. 36, 206-215 (2010).
18. Hudis, C. A. & Gianni, L. Triple-negative breast cancer: an unmet medical need. Oncologist 16, 1-11 (2011).
19. Wang, T. H., Wang, H. S. & Soong, Y. K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88, 2619-2628 (2000).
20. Singla, A. K., Garg, A. & Aggarwal, D. Paclitaxel and its formulation. Int. J. Pharm. 235, 179-192 (2002).
21. Rowinsky, E. K., Chaudhry, V., Cornblath, D. R. & Donehower, R. C. Neurotoxicity of taxol. J. Natl. Cancer Inst. Monogr. 15, 107-115 (1993).
22. US Food & Drug Administration, Center for Drug Evaluation and Research. New Drug Application Pharmacology Review 21-660. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2005/21660-ABRAXANE-pharmr.PDF (2004).
23. Li, C. et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol. 46, 416-422 (2000).
24. Tang, X. et al. Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. Cancer Res. 72, 491-502 (2012).
25. Chen, J. L-Y. et al. Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet. 6, e1001093 (2010).
26. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
27. Shelley, W. B., Talanin, N. & Shelley, E. D. Polysorbate 80 hypersensitivity. Lancet 345, 1312-1313 (1995).
28. Gelderblom, H., Verweij, J., Nooter, K. & Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598 (2001).
29. Sharma, A., Sharma, U. S. & Straubinger, R. M. Paclitaxel-liposomes for intracavity therapy of intraperitoneal P388 leukemia. Cancer Lett. 107, 265-272 (1996).
30. Lim, W. T. et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann. Oncol. 21, 382-388 (2010).
31. Hamaguchi, T. et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92, 1240-1246 (2005).
32. Gaucher, G., Marchessault, R. H. & Leroux, J. C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J. Control. Release 143, 2-12 (2010).
33. Letchford, K., Liggins, R., Wasan, K. M. & Burt, H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur. J. Pharm. Biopharm. 71, 196-206 (2009).
34. Gradishar, W. J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castoroil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005).
35. Harries, M., Ellis, P. & Harper, P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23, 7768-7771 (2005).
36. Nyman, D. W. et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced non hematologic malignancies. J. Clin. Oncol. 23, 7785-7793 (2005).
37. Miele, E., Spinelli, G. P., Miele, E., Tomao, F. & Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomedicine 4, 99-105 (2009).
38. Ernsting, M. J. et al. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J. Control Release 162, 575-581 (2012).
39. Boddy, A. V. et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 11, 7834-7840 (2005).
40. Li, C. et al. Complete regression of well-established tumors using a novel watersoluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 58, 2404-2409 (1998).
41. Zhao, T. L. et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice. Biol. Pharm. Bull. 35, 280-288 (2012).
42. Zasadil, L. M. et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci. Transl. Med. 6, 229ra43 (2014).
43. Liu, W. et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J. Control Release 116, 170-178 (2006).
44. Shamji, M. F. et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum. 56, 3650-3661 (2007).
45. Huang, X., Jain, P. K., El-Sayed, I. H. & El-Sayed, M. A. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond) 2, 681-693 (2007).
46. Martin, C. R. & Kohli, P. The emerging field of nanotube biotechnology. Nat. Rev. Drug Discov. 2, 29-37 (2003).
47. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688-701 (2006).
48. Gillies, R. J., Raghunand, N., Karczmar, G. S. & Bhujwalla, Z. M. MRI of the tumor microenvironment. J. Magn. Reson. Imaging 16, 430-450 (2002).
49. Guda, C. et al. Hyperexpression of an environmentally friendly synthetic polymer gene. Biotechnol. Lett. 17, 745-750 (1995).
50. Etrych, T., Sírová, M., Starovoytova, L., Rihova, B. & Ulbrich, K. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol. Pharm. 7, 1015-1026 (2010).
51. Zhao, C. L., Winnik, M. A., Riess, G. & Croucher, M. D. Fluorescence probe techniques used to study micelle formation in water-soluble block copolymers. Langmuir 6, 514-516 (1990).
52. Chi, J. T. et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3, e47 (2006).